Projects
![]()
No projects found
Investors
New
DAO Treasuries
DATs
Lend / Borrow APRs
Chains
Categories
Spaces
DeSci Office Hour
Recorded: June 19, 2025 Duration: 0:58:46Space Recording
Short Summary
At DSi Berlin, GoCart's Henry unveiled plans for a groundbreaking CAR T-cell therapy project, emphasizing community involvement through tokenization and announcing a new scientist joining their team. The project aims to revolutionize cancer treatment while engaging token holders in governance and funding opportunities.
Full Transcription
hey hey gmgm gmgm
jam voice echoing it's a little robot-y okay beep boop requested requested oh that's super echoey
is it yeah maybe if you mute the other version yes um how does it sound now? It sounds good.
All right. Awesome, man. How are you? How are you doing? Where are you reporting from today?
Good, man. I'm reporting from, I'm actually at my apartment in Chicago today. It's Juneteenth,
sort of a celebration of the final date that that slaves were freed in America in Texas.
And so as a descendant of slaves, I take today as sort of a holiday.
Yeah, at home, just kind of writing, doing my thing.
What about you? Where are you calling in from?
Awesome. I'm in germany actually
oh so i came here for dsai berlin and then attended molecule off site and now i'm currently in jenna
it's one of the places where actually i did my master's art it's a it's a beautiful place though
with a lot of mountains and valleys and it's very green, very international in the sense like you have one third student population.
And yeah, also the weather's been great in Germany for the last two weeks.
So enjoying German summer.
Love it.
Love it.
Is that hard to come by, like good weather in Germany? I'm not
super familiar. I've only been the one time last year. It was kind of, yeah, I heard from people
saying that these are actually the first weeks of real summer weather because it was rainy and cloudy even when I landed here until last Monday
but now it's much better. I see people going out, parks are filled, yeah very interesting time.
Nice. Love to see people at parks. Exactly. So we have Henry from GoHard here.
Why would you come and introduce yourself? So we have Henry from GoHard here.
Why would you come and introduce yourself?
Hi, I'm Henry.
And well, I'm coordinator of GoCard,
slash CEO of the Tuform company.
And I'm happy to be here.
And I also want to greet everyone from the rest of my team.
So from Aralem, our CTO,
and Chase, our token-related project lead.
Chase has to be excused
as he is attending psychedelic science 2025
right at the moment.
So quite an interesting topic there.
And I'm happy to be here.
Great, thanks Henry.
Awesome. Henry, I think we met at DSi Berlin. How was DSi Berlin for you this year? Was it your
first year attending DSi Berlin or how was your experience in general? Yes, for me myself, actually,
it was my first time at a DSi event.
As with Go-Kart, this is when I started
getting involved in DSi.
As I've heard about it as a very interesting system
to build a project like ours. And yeah was my first time was kind of a blur met a lot
like a lot of very interesting people from the fields or related fields and really had really
got involved with like both sides so one hand all the science side also
people from a pretty related field to what we do and also learn a lot about the token side
and the dsai side
love that love that the best side oh yeah love it
love that love that the best side oh yeah love it
and the rave was great oh yeah i bet man i'm so upset i missed the rave this year
yeah so barlin and i met last year at least i berlin and uh yeah we we quickly became good buddies. And here we are hosting the show.
And I think, yeah, DCI Berlin offers everyone new moments in relationships and business deals and all of that.
Like a lot of prospects, right? positive vibe now uh in the ecosystem because now at dsai berlin we kind of had that conversation
with a bunch of different people who are building in the dsai ecosystem so it was very interesting
to see uh people like henry coming up and um yeah a bunch of new folks into dsai uh i wonder how it was for you uh henry uh was it little overwhelming uh in terms of
different projects that are that are you know expanding and building on dsi or was it just
you know you felt bullish on uh the dsi ecosystem intent how was it for you it was like well like
It was like a bit of it was like stepping into new worlds.
I was like the classical science as I handled the classical cell therapy science behind The governance side, how to build tokenized on-chain work
was quite a big learning curve and quite a lot in a small time
frame, but really, really fascinating, I must say.
Interesting.
Interesting to know that. Yeah, how was it for you carlin uh you might be for moing a
lot living uh sitting at chicago missing d thai berlin but i know you are cooking something bigger
and uh how's it going for you man for mowing a lot um i think my favorite my favorite talk
personally i'm a little biased, was the pump science,
Benji getting up there to speak about what pump science has coming next.
For folks that don't know, I'm also a drug dev. In addition to the work that I do with Molecule,
I'm what's called a drug dev for pump science. And so we're soon going to be launching 17 new compounds to be traded on their on their like longevity token platform.
Some really cool new and exciting like bonding curve stuff that's going to hopefully like get rid of the those like snipers that can come in sort of on these what are supposed to be, quote unquote, like fair launches.
So, you know, that they should be launching anytime now, be on the lookout. But yeah,
other than that, I, I mean, just great talks.
It's really cool to see how in just a short amount of time in just the year
where I thought that Desai was pretty, you know, pretty big.
And then you learn that it's small. Then this year,
there's been like this almost like explosive growth.
We figured out some things that work, some things that don't work. And, you know, everybody is sort of, you know, there's a there's been a few pivots from people that, you know, spoke last year.
And it's cool to see how people are reinventing what, you know, their focus is the same.
But, you know, the the path that you take to get to your end goal can change all the time.
And that's where I think that, like, it's been so cool to see how Desai is this almost like adaptable form of the of the, you know, the scientific method that we've been working with for so long.
And it's just really, really cool to see.
So, yeah, big FOMO.
I hope you guys didn't get too much merch that i can't i can't wear i'm just
gonna have to be jealous of all the pictures and stuff yeah man definitely i think uh wonderful to
see like what's uh happening with pump side i got a um i got a good opportunity to be with benji for
the last few days and uh at the offside we spoke a lot and yeah super bullish
on what you guys have for the future and yeah so now we have GoCart here Henry from GoCart.
I want to do it this way so Carlin is the science guy here so he's going to take care of the science
part. I just want to know uh from you henry
how do you think tokenization kind of creates a new uh incentive layer for go-kart and it's you know the patient community it serves how are you guys planning to utilize this you know new
tool of tokens and what sort of utilities are you guys thinking of? Actually, Kijo, I think maybe we could start with like a general,
can you just maybe Henry explain to us what GoCart is?
Like what you guys are looking to,
what problem you guys are looking to solve
and what's the science behind it?
Maybe before we get into the token stuff.
Sorry.
So, well, let's then let's start with the science.
So GoCart comes from CAR T-cell therapy, which in fact means chimerous antigen receptor T-cells.
And what this means, if someone has a cellular disease, normally used in cancer, also slowly trickling into autoimmune diseases, and maybe in the future chronic viral diseases.
Then the mode of action is we take immune cells from the patient.
We normally use T cells, T killer cells, but natural killer cells and K cells are also possible.
And then those cells get genetically engineered.
And they get genetically engineered with an artificial receptor, the so-called
chimeras antigen receptor, and then we can put them back into a patient. And with this receptor,
these cells can find their target cells, the tumor cells, and kill them all. And this already had
some tremendous impact into the treatment of specific blood cancer
cell types.
I'm talking about the so-called CD19 or BCMA CAR T cells, which are already approved and
on the market.
But they also are like a good example for a big problem that still needs to be solved before CAR T cell can really be of broader
use across entities and for very different kinds of tumors.
So the main problem that still remains is so-called on target of tumor effects.
So when we get back to what exists, we got these CD19 and BCMA CARs.
They're called like this because they are for the targets, CD19 and BCMA, and they are chosen in a specific manner.
As a CAR T cell kills every cell that has this target, the target is a surface antigen on the cell,
you can only use those targets that are on tissue you can live without. So C19 and BCMA, a target in several types of
blood cancer, diffuse large cell B-cell lymphoma, ALL, for the BCMA car, it's the multiple myeloma. They all are specific for subtypes of B cells.
And if you kill them often, lose them while killing cancer,
you can live without that.
In the worst case, the patient has to substitute immunoglobulins
for the rest of his life, which is nasty,
but still is better than dying from cancer. But this kind
of luxury is actually pretty rare among tumors. Most good cancer targets, my example is CD56,
are also on essential tissue. CD56 would be way better than, for example, BCMA. I already told you these are on the market.
Higher expressed can't be downregulated so the tumor cannot escape, but it is also on
like every neuron in your brain. And killing those off is kind of counterproductive. So
what would be a good solution is a so-called end gate.
And this is where we come to what we develop.
With an end gate, you pick like a combination
of two different targets.
You could combine CD56 with a marker that is not together
with CD56 in nature.
You could take CD38 for the multiple myeloma. Those never occur on the same
cell, but they occur on the same cell if this is a multiple myeloma tumor cell. So we can tune our
CAR T cell to only kill like this one cell that has them both and leave alone any types of cells that have only one of those
then we can selectively kill off the tumor and spare everything else and your brain is safe
so there were some approaches to get this done in the past
There were some approaches to get this done in the past.
Most of those are leaky and have a reduced killing of single antigen cells, but still kill them.
So you can't use something like CD56 with this.
It would still kill your brain, just slower.
First, a system, so-called link cars, came out last year.
They actually have a good end gate that does not kill any on target of tumor cells, but
they have the problem that they do this intracellular and they use so-called downstream molecules
in the signal cascade.
So normally when a car gets activated,
it activates the normal signal cascade of a T-cell receptor
that has one molecule that activates hundreds of the second,
and each of those activate hundreds of the third one, and so on.
So the signal is amplified through this process.
And for their end gate, you have to go way downstream to the third
part in this cascade so you lose on on a lot of enhancement and if the tumor expresses low level
of your target this type of cells will fail so then we at go-k, we started to think, why don't we move all this outside?
Why don't we use a normal car with the whole signal cascade, but, CAR T cell trunk, the same viral vector,
the same thing you engineer on every CAR T cell.
Should also cut down costs in the long term as it can be mass produced for whatever tumor
or whatever disease you want to target.
And in addition, the patient gets subcutaneous ant-gate binders. So this
is a small part of an antibody with a linker and an artificial domain we develop, and they
have an A and B configuration. And the patient gets them subcutaneously and it moves around through the bloodstream and finds their target cells.
And if a cell now has both antigens, then our domains A and D form a heterodimer. They bind
together and in the end, this is the only configuration where our common car trunk can bind to them.
So we recognize the ant gate cells that have both antigens
and kill them off, but we do not recognize any cells
that have only one binder and your brain is left alone.
And we can do this without harming the cytotoxicity because we have the whole signaling cascade intracellularly.
So this in short then, no not really short, but this is a total how our system works and
yeah then she'll open the field of power T cells up to a whole range of new antigens that are
just too dangerous right now to use and to open them up to a lot of different tumor types
that can't be targeted right now, but with our system, they can.
That is really cool, Henry.
Thank you for sharing. I love the sound of like a mutually exclusive, like CAR-T system that's able to sort of get these really specific, you know, really specific binding partners.
Like not only are you guys able to, you know, address these tumors that have previously been untargetable, but now it looks like maybe you could even improve some of the existing CAR T systems that are out there.
So I think that that's a really cool, really great way to, you know, make your mark and sort of differentiate yourself in the field.
And so, you know, following on that, maybe we can then get to Kehoe's question that, you know, what made you, what sort of brought you to like DSI and what made you think that this was sort of the, you know, tokenization and all that were the ways to go for, you know, supporting this project.
Yes, so this is actually the point where we have to go to, well, how do we realize this?
As we as a project have been building So in reality, we need to get into
an S2 bio lab and do the work, run the candidates for our binding trimer that are spewing out by the prediction engine run them through a cell culture
detect collect the data on their actual binding and stability properties in a human cell line
and then find the ideal primer we can then put out to secure the IP and proceed with an animal and clinical trial for this.
And this is then kind of the problem when you try to do this through the traditional
system. So the VCs out on the market, they always rely on on some university already delivering you a pre-produced patent on the silver plate.
But we also need a bridge to get to exactly this point. This then brought like a molecule and DSi as an environment to the place as it's like unique new environment where projects at this stage can be funded and at the same time community govern.
And also this is it by the community.
So in the end, we put out an IP token, an IP fungible token in this case, where people
can buy themselves into the development of our system early and then profit from governance
over the exploitation of the ip so we of course hope that people will vote to let us
develop this further in our startup and explore and exploit this more and at the same time
being being in early as well having a risky investment with quite a big
possible return
quite a lot of
VCs they mirrored me that
yeah we would so jump
on this project once the patent is
there so
there actually is then the option it is up
to vote what actually will be done
so it might be
possible to once turn our new token gcrt
dollar gcrt is the name into a an equity holding token for parts of go-kart when we develop it
further or if people feel more like yeah we want to cash out quick then there can be a buyback scheme or maybe third option for a longer
term rent of the IP than when we generate revenue that there is a monthly compensation
for every token holder in ETH or something else. So these are like the three main options to cash in on our success for
supporters. And at the same time, well, we have the governance model. And one more very interesting
thing about DeSci for us is we also invite our token holders and our collaborators to propose new targets for us.
And we want to use wisdom of the crowd.
As we are in the end like a platform technology.
So we have, of course, beachhead markets.
We want to do a CD38, CD33, and CD56 binder at the beginning.
Next one would probably be a drop two for the small cell lung
carcinoma. But in the end we want to be an open platform where every company or research group
or in the end people from our DSI community can propose interesting new targets they found.
They found them on the human exome browser on the internet or are related to some
of their own research and can just suggest us interesting targets that we might add to our
platform in the end or that some collaborator might add to our platform in the end we want
we also want to license out these binder development so interesting research groups
and companies can develop their own binder hang our a and b domains on them if they want and start
exploit them their cell themselves with us taking like a small fraction of revenue and at the same
time we provide all the cell related stuff so we are the one giving people like the common trunk and different configuration of car T and car and K cells to use with the whole system. makes our platform more valuable and at the same time adds more versatility and more options and
also fallback options to each and every doctor and each and every patient to really tune the
whole system to an individual patient's needs and expression pattern on the tumor and also if the portfolio is big if the tumor gets resistant and
the patient like loses the CAR T cell therapy the binder can be swapped out the new binder
can be used and it should work again instead of like it is right now that the whole therapy is lost,
and normally people don't get a second one,
sadly, as they're pretty expensive, especially the cartesol
infusion at the beginning.
This is super great.
Like, I'm super interested in your gokart solution uh i just want to understand from
a patient perspective let's say let's say i don't have any use case for carty but in future it can
be used for a bunch of ailments that i as a person or anyone who thinks from the patient angle would
think about so what is my exit if i kind of get into the CAR T project?
What's the incentive for me or apart from the financial incentive or whatever
as a patient like can I get to would I have like early access to the product or
would I get to be the part of you know any of these first trials. Do you have any ideas on that?
So this actually is a matter of discussion.
So I think it would be very good to shortlist token holders
in our clinical trials.
So what we can offer is to get in our phase one and phase two.
So it will be probably phase one, phase two trial to get in our phase one and phase two so it will be probably phase one phase two trial to get
get in there as patient first if needed or this may be something up to discussion because we of
course want to deliver the system early and as into as many people as possible but there have
been pharma companies that got them problems with the actual approval by doing this.
But we might still also offer compassionate use cases to our token holders.
So if you have some exclusion criteria for the actual phase one or phase two trial,
the actual phase one or phase two trial we could still provide you with the treatment
as an individual trial patient so this is not all jurisdictions allow this in their
medical field sadly but many do and this is things that are possible if you like are from the patient or the patient
advocate collective as we understand that of course this system is filling a gap that where
not much is on the market right now so in the end we want to as much people as possible to join the cohort and get onto the
studies.
And if there are eligible people among the token holders, then they definitely are shortlisted
for the compassionate use and the phase one, phase two trials.
In the end, we aim to get orphan designation, orphan approval.
This is why we decided on the B-shot markets of multiple myeloma and acute myeloid leukemia,
as these types of blood cancers have had this in the past in the relapsed and refractory state and still but still lack a real treatment option so even
the bcma car patients eventually relapse because bcma is regulated down at the end
in the the multiple myeloma and the aml has nothing but definitely any anyone who is in our environment and then has the need for these kind of treatment
or can use them or has a relative that might use them, then is invited to be referred to
us and join our clinical trials as soon as we're ready for them. That's awesome. I will hit up anybody I know to see if maybe they're interested. I really
think that it's a great opportunity. You said there's a lot of options or not a lot of options
for people currently.
And I think that it's, you guys are providing a really cool opportunity to almost like exponentially
increase those options, which I think can only be a good thing because like you said,
there's all these different, like very specific types of these cells, as well as, you know, the,
what is it? The, a big prohibitive thing for cell therapies currently is
how expensive they are. And, you know, like you're saying, the possibility of maybe, you know,
shortlisting so that people can get these treatments that they need, or even, you know,
providing some sort of monetary incentive to allow people that wouldn't normally be able to afford access to these sort of
therapies to you know try out you know your very very um very early on uh versions before we get
to the trials um i think one thing that i'm also kind of wondering is you know what perhaps is your
timeline you guys are looking at for you know getting where you at currently i
guess and then what would you maybe hope for or predict for you know getting to that like phase
one trial uh stage yes so uh our current race of course is to get the in silica proof to be in vitro proof itself so
these 500k we raise are for a one-year timeline where like the first half is reserved to test
a lot of different yeah or of different vectors with different uh binder candidates through the
cell culture pipeline and the facts and uh next step would be expressing like we have part abc
binding part expressing part c as a car and then doing like in vitro killing experiments with the car T cells from
cell line and tumor cell lines. So this is for will be like two instances of IP.
One should happen right after we found a good working candidate for the ideal primer.
Must not be the one ideal primer that's there in the end in the actual car, but one that proves the system.
the end in in the actual car but one that proves the system and the second one is then the car
with these with this specific peptide as an engager so this is like uh part part one for
about a year and then of course we have to prove in animal trials.
So there have to be two animal trials and one will be the tox study for the binders
as they are like in a peptide compound and they have to undergo toxicology studies. And the second part, the real functional part,
is in mouse, so-called NSG mouse.
This is a immune system lacking mouse
where human tumors and human immune cells can be transplanted.
So we can test out like in a in vivo environment
that we can actually kill off a 3d tumor with the
system not only in in like a 96 well plate but actually in something that is like tissue
and then after this with positive results we can start applying for the first phase one.
Phase one is a rather small trial with the animal and clinical trial from the authority
side.
So we might short track this a bit by going to the US or China with our animal trials.
So normally in Europe, especially Germany, it is about one year of time to get approval and really start with animal trials.
I actually know colleagues that had to uselessly kill off mice because they grew too old to do the experiment while the authorities were scrutinizing the approval and in the end they had to start over
so this is something we definitely want to avoid on one hand because it's a waste of laboratory
animals and it is useless in the end and the opposite of what animal protection should be and of course this slows
the process down so we might short track this by moving the animal trials to a jurisdiction where
approval processes are faster and with this whole we plan like one year of in vitro and then maybe one two years of in vivo so maybe end
of 2027 beginning 2028 we might start applying to the first uh uh yeah to for for the first IND enablings and then start with the clinical study once that is approved,
which I said I cannot really predict when this happens as all the different jurisdictions have
very different timeframes. So the FDA and the EMA are very different in this regard and
are very different in this regard.
And if we get into other places globally,
there will be different timelines
and different procedures for those countries alike.
But yeah, 2028, 2029 might be a possible start date
for the first inpatient trials.
Cool. And honestly, that's faster than, you know, certain things getting to, you know,
getting to these trial phases as if they were done traditionally. So even though it will
know it will probably take a few years that's still you know seems to be a more efficient
probably take a few years, that still, you know, seems to be a more efficient
uh way of going about getting this approval so that's really cool that you guys are doing that
um what uh just just one more question i just want to add it on to henry and carlin um do you think
pump science would uh reach a stage where we could test like initial, you know,
sort of analogs of this technology with any of the animal models?
Because now we have worms and insects basically in the pump signs because the focus is longevity.
But then we could also start looking at relevant models for different use cases,
will that be something we can see in future when, you know, let's say in a couple of years,
do you think this could be a chance for pump science as well to integrate into this?
What do you guys think?
Just an open question.
I think that might be possible.
Maybe what's more likely is that the powers that be might use the like technology and the like methods of the pump science platform,
maybe as opposed to like using pump science itself, just because I think that there's some, like Henry was saying, there's
a lot of like regulatory things that come into play as soon as you start talking about, you know,
a treatment or for something versus a, you know, a supplement, because longevity is not necessarily
considered and, you know, an indication that you can target. so maybe a little bit different for like these cancer and
autoimmune sort of therapies but what do you think henry yes so
so this of course depends on if these binders are found there. So basically, pump signs probably can be a space
where these antigen hunt happens.
And then in the end, well,
the binders normally are derived from antibodies.
So this works like we find a target
and then we run either an immunization of an animal or today there's also AI engines
upcoming that can simulate these immunizations and can put some candidates, binder candidates,
that do not really look like the original antibodies anymore, but are derived from these
kind of structures. And this might be a part in it, but of course it is not like traditional
compounds that are sought after there. It's more like a very specific thing for very specific antigens.
And in the end, of course, we want them to have some kind of selectivity and expression
so that we can combine them in a way that we can find these two are only on the tumor.
And this kind of is the requirement.
So there is some difference to
what is on pump science right now but in in principle i think pump science can be an instrument
for this i like that idea uh pump science is all about like gamifying science. So, you know, turning it into like a pattern recognition game for, you know, finding these different antigens that, you know, exist on one very specific type of tumor versus another could could be a fun way for people to get more engaged with the science and, you know, learn more about the go-kart system as they're going and also maybe like you know contribute and
be incentivized to um you know keep trading on the pump science platform i think that's a cool idea
henry yeah so we might we we are not there yet but we might implement this in the future
yeah if you're interested let me know i'll i'll link you with benji and we can we can
get it going but we'll get we'll give it some time we'll give it some time of course yes
awesome i think uh this is how new collaboration should be built uh using the systems that we built
the systems that we build.
And yeah, super happy to discuss this with you, Henry.
And how is it going with your project as of now?
Who are all in the team?
Can you talk about your team and who is doing what?
HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY HENRY yes so we are by now a team of three uh mike's still on board one more scientist so there is me myself and around him on the science side i have the background of the car t-cell therapy so
i'm a medical doctor and i did my doctoral thesis like more extensive project for medical doctor
did my doctoral thesis like more extensive project for medical doctor in the field of
car and k cells actually where i co-express them with an artificial receptor
with a chemokine receptor to hunt down the tumor cells in the actual site where they are
cells in the actual site where they are and actually found that they got more cytotoxics
so this kind of then got the main topic of the thesis so in in this regard i bring the
expertise of cell engineering and how to design cars to the table and then we have aralem
the table and then we have aralem so so i'm from uh charitie berlin and then we have aralem she's
from nazar baiv university in uh almaty kazakhstan actually so we met at last year's cohort of igem
startups where we went through with the project and where the project was formed and she has a background in
design of nano bodies and antibodies so she gives into more expertise about like targeting and
finding binders to us so this like is a really good match to pull off a system like this
It's a really good match to pull off a system like this.
And then we have a collaborator, Genki IT is a company where we have a contract to co-develop
our auto predictor, like the engine that spews out our candidates. then we have chase who we met at the uh yeah the d side course at molecule and he's like our
project lead for everything token related and company related and has quite a good track record in corporate America.
So he also worked for Tesla and for X for a while
and also is experienced with crypto and trading
and therefore was awesome to have him aboard with this.
to have him aboard with this so he's like us three building now and um yeah then we have a net
So he's like us three building now.
a network of scientific advisors in the cartesel fields who we can call upon some specific questions
Sounds like a great team.
Is there any, maybe anywhere your team needs some extra help, any call to action or anything
like that?
Any way that the community can come together and support you guys as a team right now? For once, of course,
the community can buy our token
GCRT.
yeah, we, I briefly
mentioned, we actually are
onboarding one more
scientist right now.
To join me at the laboratory as
the timeline is for me to start off
with the laboratory work,
which might in Berlin, but also a at the laboratory as the timeline is for me to start off with the laboratory work which
might in berlin but also a novel development maybe we could relocate to cadiz spain to use some synergies with the the department of car t cells at this university but still in the making this this thing so one more interested person that is from the field
and is interested is very welcome to join like in autumn beginning of winter and oralum will
join the laboratory like next year so we're still open for more people.
That's fantastic news.
So people who are tuning up, go reach out to Henry
if you are interested on the project,
and if you think this is something
that you guys are interested in building.
And I think there is a lot of possibilities
to collaborate with a bunch of other projects in DSi as well.
Yeah, I think that's one good message
that came out of DSi Berlin.
The potential to build as an ecosystem is so huge.
yeah, betting on that.
Yeah, betting on that.
Yes, yes indeed.
Yes, yes indeed.
Awesome.
So, yeah, Karin and I were thinking about
making this a show,
which has been a discussion for a long time,
inviting speakers to discuss more on DSi, invite builders in DSi like Henry
and showcase what they are building to the ecosystem. So probably we are working on a
different time slot for this event to happen where more people can join in and yeah please use
dsai office hours as your forum to to raise your questions and legit concerns on the dsai ecosystem
and all of that yeah absolutely and you know if you have suggestions for projects we should talk about, something you're working on, something, you know, a friend of yours is working on, but they don't have X or something like that.
First off, get them on X. What are they doing? Second off, just let us know, comment on the, you know, the Office Hour post and, you know, we'll try to incorporate people's ideas as the
show continues to evolve. As long as I can geek out about science and keep working with my boy
Kehoe and talking to people like you, Henry, I'm going to be all right.
Yes, indeed. Well, of course, everyone's also invited to join our ex or our brand new telegram channel not a lot yet going on on the telegram
channel but it will come up and this is where the freshest updates will pop up
nice do you have a a sort of regular schedule that you plan to update the telegram and stuff like that or will it just sort of be as results go so i think of once we
start with the laboratory work of course we give some updates for building the lab like we we
established a new experiment and stuff like this or we run through uh 50 new candidates or 20 new candidates this week or something like this.
And then as we rank these candidates, we can also have a tracker on there where we can
kind of haggle on the candidate that might win or if there might be a new up and coming
star in there that no one noticed before.
So this kind of for the start and then regular updates of as the work goes.
So think of maybe once we start operation to do something like twice a week or something.
of maybe once we start operation to do something like twice a week or something and of course
instantly once an interesting new candidate or result is coming up
awesome live news feed you heard it here guys tune into that telegram
yes i think this is a great opportunity um and and it's interesting to see how you think about,
you know, keeping this project active for the funders and the community.
I think this is something definitely is.
All different projects should try to be, you know, more transparent on what they are building,
regular updates, keeping it a little more interesting.
I think POMP Science is a great example, which showed us how this could happen.
And probably we need to build more of these systems to, you know, make it super, you know,
simple for normal people to kind of, you know, adopt and use these tools.
So, yeah, interesting to see the development of where GoCart is going.
And just I'm curious, who is taking care of the Twitter
account?
And do you guys have a community lead
who is doing this actively more sort of,
or is it just like the team shares it?
So this is like shared.
So at the moment, it's a more shared project between Chase and Aralem.
So do like the reach out and regular updates right now.
And then, well, of course I provide with novelties from my site and we like put everything together
and then normally Chase or unwrite a post.
So this is how it works by now.
Great.
I think, yeah, getting close to the-
I see you there.
Yeah.
I don't see any speakers.
But yeah.
All right.
I think just upping the Twitter game close to the launch
can then sort of bring your community closer to get all the feedbacks and all of that.
I think, yeah, that is also one of the important points, which is very native to DISA, which is the community part.
So I think having that, as you guys are like rightly focusing on the community part, I would say, I think upping the X game as well,
closer to the launch can really help you,
create that sense of branding and all around that.
Yeah.
Yes, indeed.
Awesome.
All right, guys.
So just a couple of things uh from my side um because i was
super interested to make a dsai recap like a dsai berlin recap for everyone who is tuning in here
but we had a a great opportunity to talk to henry this week so i think next week we'll do a proper dsai berlin
recap bringing in some of the speakers from dsai berlin probably henry you are also invited to join
the next call um the idea is to you know sort of do a reflection back at the event um what did we
learn what did we agree upon uh what are going to be the next steps and all of
that and um a little alpha from me that's that i got super excited by a bunch of projects that are
that's happening in the ecosystem and thought why not do a dsci pop-up city uh for dsci and
use this pop-up city to organize different trials and bridge different communities,
build these bridges between, let's say,
DSi and Deepin, physical infrastructures or AI.
Yeah, a bunch of other features,
probably governance, different tracks.
And the idea is to see what happens
if we put all these interesting DSi builders in one space and then give them infinite resources to build new stuff.
What would they come up in four weeks? That's the idea. The experiment is just that. Right.
Can we kind of, you know, reflect on what we have been doing so far and then set the precedent for DSiV2 or something
greater, right?
So this idea is something very native that started at DSi Berlin.
So anyone who is interested to, you know, organize or build this from bottom up, yeah,
please, please hit me up.
And yeah, we have a public telegram channel where people can join and come up with their ideas,
either for trials, speakers. Feel free to bring your ideas.
And the first idea that we need is a vote on where do we organize this event?
Because there are a bunch of cool places across the world and we have
Def Connect happening this fall in Argentina, Buenos Aires and there is also like a lot of
pop-up villages around at that time. So yeah a bunch of cool things coming up so we need to
plan it accordingly and then yeah this is something sort of the the next cat next
catalyst for um yeah dsai ecosystem oh yeah let's push it this sounds awesome
all right so uh carlin any any closing remarks we We are on top of the time and do you have any?
Yeah, I'll just say I'll throw out there. Let's have our DCI pop up in Chicago so I can easily get there.
We should, man. I think we should, yeah. At the very least, we could do a meetup, if not a full pop-up city.
But yeah, looking forward to, you know, next week we'll talk a little bit more about some
reflections from DeSai Berlin.
I can live vicariously through those that actually attended.
Photoshop myself into the final picture that everybody took.
And yeah, we'll be here probably a different time next week.
We'll figure out what that's going to be
and announce it as soon as possible.
Looking forward to talking and hearing from other people.
And yeah, just stay strong in DSI
and spread the word as much as you can.
Thanks for listening.
That's neat. Thanks for listening. Suneet, thanks for having me.
Awesome, thanks for joining Henry.
Thanks for joining Karlyn.
And yeah, I think now I'm super bullish on D-Sci
after D-Sci Berlin, a lot of positive vibes
around Twitter and IRL and all of that.
Yeah, super happy to keep up this
vibe and uh super grateful uh having a spot to build in this ecosystem um yeah i see a bunch
of builders here on the space um so yeah keep building uh there's a lot more to come this is
just the beginning of the beginning of the beginning so we have a long way to go with that
signing off.
Bye, guys.
See you, guys.
Adios.
Thanks, guys.
Bye. Thank you.
